DOCSLIB.ORG

| Hao Wala Naman Takia Pilot at an Wa Aina Tatti

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
| Hao Wala Naman Takia Pilot at an Wa Aina Tatti |HAO WALA NAMAN TAKIAUS009920379B2 PILOT AT AN WA AINA TATTI (12 ) United States Patent (10 ) Patent No. : US 9 , 920 , 379 B2 Bentwich et al. (45 ) Date of Patent: Mar. 20 , 2018 ( 54 ) NUCLEIC ACIDS RELATED TO ( 2013. 01 ) ; C12N 2310 / 531 (2013 . 01 ) ; C12N MIR - 29B - 1 -5P AND USES THEREOF 2320 / 10 ( 2013 .01 ) ; C12N 2320 / 11 ( 2013 . 01 ) ; CI2N 2320 / 30 ( 2013 .01 ) ; C12N 2330 / 10 (71 ) Applicant : Rosetta Genomics Ltd ., Rehovot ( IL ) (2013 .01 ) ; C12Q 2600 / 106 (2013 .01 ) ; C12Q @ 2600 / 136 ( 2013 . 01 ) ; C12Q 2600 / 158 ( 72 ) Inventors : Itzhak Bentwich , Tel Aviv ( IL ) ; Amir (2013 . 01) ; C12Q 2600 / 16 (2013 . 01 ) ; C12Q Ayniel, Tel Aviv ( IL ) ; Yael Karov , Tel 2600 / 178 (2013 .01 ) Aviv ( IL ) ; Ranit Aharonov , Tel Aviv (58 ) Field of Classification Search None (IL ) See application file for complete search history . @( 73 ) Assignee : ROSETTA GENOMICS LTD ., Rehovot ( IL ) (56 ) References Cited U . S . PATENT DOCUMENTS @( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 7 , 250 , 289 B2 7 /2007 Zhou 7 , 407 , 784 B2 8 /2008 Butzke et al . U . S . C . 154 (b ) by 0 days . 7 ,655 , 785 B1 2 / 2010 Bentwich 7 , 820 , 809 B2 10 /2010 Khvorova et al . ( 21 ) Appl. No. : 15 /586 , 747 2005 /0075492 Al 4 /2005 Chen et al . 2005 /0261218 AL 11 / 2005 Esau ( 22 ) Filed : May 4 , 2017 2006 /0247193 AL 11 /2006 Kazunari 2008 /0125583 Al 5 /2008 Rigoutsos et al . 2008 /0269072 Al 10 / 2008 Hart et al. (65 ) Prior Publication Data 2012 / 0094374 Al 4 / 2012 Bentwich US 2017 / 0298447 A1 Oct. 19 , 2017 2014 /0017780 A11 /2014 Bentwich 2016 /0046935 A1 2 /2016 Bentwich et al . Related U . S . Application Data FOREIGN PATENT DOCUMENTS (60 ) Division of application No . 14 /756 , 185 , filed on Aug . 13 , 2015 , now Pat. No . 9 ,650 ,679 , which is a division wo 2003 /029459 A2 4 /2003 of application No. 13 /986 ,516 , filed on May 8 , 2013 , WO 2004 /016317 Al 2 / 2004 now Pat . No. 9 , 133 , 453 , which is a division of application No . 12 /661 , 041 , filed on Mar. 10 , 2010 , OTHER PUBLICATIONS now Pat. No . 8 ,461 , 315 , which is a division of Apr. 18 , 1997. “ EST28528 Cerebellum II Homo sapiens cDNA 5 ' application No. 11/ 130 ,645 , filed on May 16 , 2005, end .” XP002630735 . now Pat. No. 7 , 709, 616 , which is a continuation of May 16 , 2002 . “ Homo sapiens miR - 102 - precursor - 1 micro RNA , application No . PCT /US2005 /016986 , filed on May complete sequence . ” XP002630736 . 14 , 2005 , and a continuation - in -part of application Jan . 16 , 2001 . “ CM3- RT0006 -091200 -545 -505 RT0006 Homo sapi ens cDNA , mRNA sequence . ” XP002630737 . No. 10 /709 , 577 , filed on May 14 , 2004 , now Pat . No . May 16 , 2002 . “ Homo sapiens miR - 102 -precursor - 7 . 1 micro RNA , 7 ,687 ,616 , and a continuation - in - part of application complete sequence .” XP002630738 . No . 10 / 709, 572 , filed on May 14 , 2004 , now Pat. No . “ Human Genome, U95 Av2” , Oct . 2 , 2002 , XP002215481 , http :/ / 7 , 888 , 497 . www .affymetrix .com . “ GeneChip Human Genome U133 Set” , Feb . 26 , 2003 , (60 ) Provisional application No . 60 /666 ,340 , filed on Mar . XP002232760 , http :/ / www .affymetrix .com /support /technical / 30 , 2005 , provisional application No . 60 / 665 , 094 , datasheets / hgu 133 _ datasheet .pdf . filed on Mar . 25 , 2005 , provisional application No . Constantine L . et al ., “ Use of genechip high - density oligonucleotide arrays for gene expression monitoring” , Life Science News , 60 /662 ,742 , filed on Mar. 17 , 2005 , provisional Amersham Life Science, US , Jan . 1 , 1998 , pp . 11- 14 , application No. 60 /593 ,329 , filed on Jan . 6 , 2005, XP002964122 . provisional application No . 60 /593 ,081 , filed on Dec . Nov . 16 , 2001, “ Mus musculus 16 days neonate male diencephalon 8 , 2004 , provisional application No . 60 /522 , 860 , filed cDNA, Riken full - length enriched library , clone : G630058E01 , 3 ' on Nov. 15, 2004 , provisional application No . end partial sequence. ” , XP002630739 . 60 /522 , 457 , filed on Oct . 4 , 2004 , provisional application No . 60 /522 ,449 , filed on Oct. 3 , 2004 , (Continued ) provisional application No . 60 /522 ,452 , filed on Oct . Primary Examiner — Dana H Shin 3 , 2004 . (74 ) Attorney, Agent, or Firm — Polsinelli , PC ; Rob Ron Galant ( 51 ) Int. CI. C12N 15 / 11 ( 2006 . 01 ) (57 ) ABSTRACT C12Q 1/ 68 ( 2018 . 01 ) Described herein are polynucleotides associated with pros A61K 38 / 00 (2006 . 01 ) tate and lung cancer. The polynucleotides are miRNAs and C12N 15 / 113 ( 2010 .01 ) miRNA precursors . Related methods and compositions that (52 ) U . S . CI. can be used for diagnosis , prognosis , and treatment of those CPC . .. .. .. .. .. C120 1 /6886 ( 2013 .01 ) ; A61K 38 / 00 medical conditions are disclosed . Also described herein are (2013 .01 ) ; C12N 15 / 111 ( 2013 .01 ) ; C12N methods that can be used to identify modulators of prostate 15 / 113 (2013 . 01 ) ; C12Q 1 /6809 ( 2013 .01 ) ; and lung cancer . C12N 2310 / 14 (2013 .01 ) ; C12N 2310 / 141 3 Claims, 5 Drawing Sheets US 9 ,920 ,379 B2 Page 2 ( 56 ) References Cited OTHER PUBLICATIONS Dec . 6 , 2000 , “ UI- M - CG0p -bqm - b - 04 - 0 -UI . s1 NIH BMAP Ret4 S2 Mus musculus cDNA clone UI- M - CG0p -bqm - b - 04 - 0 -UI 3 ', mRNA sequence . ” XP002630740 . Bartel D . P ., “ MicroRNAs: Genomics , biogenesis , mechanism , and function ." , Cell, vol . 116 , No . 2 , Jan . 23 , 2004 , pp . 281- 297 , XP002359089. Lee R . C ., et al. , “ An extensive class of small RNAs in Caenorhabditis elegans ” , Science , American Association for the Advancement of Science ,US , vol . 294 , No. 5543, Oct . 26 , 2001, pp . 862 - 864 , XP002284273 . Lewis B . P . , “ Prediction of Mammalian MicroRNA Targets ” , Cell , Cell Press , Cambridge, NA , US , vol. 115 , No . 7 , Dec . 26 , 2003 , pp . 787 -798 , XP002295226 . Grad Y . et al ., “ Computational and Experimental Identification of C . Elegans Micrornas” , Molecular Cell, Cell Press , Cambridge, MA , US , vol . 11, No . 5 , May 1 , 2003 , pp . 1253 - 1263 , XP009032050 . McManus, M . T ., “ MicroRNAs and cancer, ” Seminars in Cancer Biology, 13 : 253 -258 ( 2003 ) . Calin , G . A . , Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers , PNAS , 101 ( 9 ) : 2999 - 3004 (2004 ) . Paul, et al. , “ Inosine exists in mRNA at tissue - specific levels and is most abundant in brain mRNA , ” 1998 , The EMBO Journal , vol . 17 , pp . 1120 - 1127 . GenBank Accession No. BB017822 , last updated Jun . 22 , 2000 . GenBank Accession No . BF019006 . 1 , last updated Dec . 29 , 2000 . Lagos - Quintana , et al. , Identification of tissue -specific microRNAs from mouse, 2002 , Current Biology , vol . 12, pp . 735 -739 . U . S . Patent Mar. 20, 2018 Sheet 1 of 5 US 9 ,920 ,379 B2 FIG . 10 FIG . 18 FIG . 10 TOHANA HR ANA CLEAR SGALL , SNOOR, Rus , , inte 20 iix is Antissists FrestiRNA PER ANNA . TENE ANA Osake SAMA Tags Mats egorise INN INNA Asso . ARRY ANNA wittin ASA | ature it it ! Mait rait T ai INTAS Nen int ite it text it NAANS TANIA U . S . Patent Mar. 20 , 2018 Sheet 2 of 5 US 9 ,920 ,379 B2 AK www . .. 23493430 . ... 412413414415 83 83 ** * * ** * ** ** 02431432 - - * * 40AT . - - WPQMOV 49 37837737 st 429430 - man . - A - - - 428 - 4 YRNA Quote 450:47 - . rrrrrrrrr 4552 000 414243 424425426 - - - - 4331 AJA - B 642 423 40 12 - - A 100910 437438439 619 420421422 436 - A18419 - - -- FIG.2A FIG.2B U . S . Patent Mar. 20 , 2018 Sheet 3 of 5 US 9 ,920 , 379 B2 800 . .. .. .. .. .. 600600 700 600 500500 11111111111111 i 400 300400 300400500 Locationonalignment 300 Locationonalignment ..da K 200200 .200 . Iwata ne 100 HomoSapiens 100 Pantroglodytes 0 FIG.3A de o There SCO FIG.3 Score U . S . Patent Mar. 20 , 2018 Sheet 4 of 5 US 9 ,920 ,379 B2 . MYYNY . SKOWEEN . voisirs WWW. * FIG.40 en Det ES COOTERSOMOCIO :* S * * : 1. M .XY *778 :.*234 :.* 7 * *26. .* Ort:30* *-7628 *O : :XY300* :7*, 3:20 :* ?38*. * * 26-28 *7: >*: * :* * :* 2* * :* * XXX* x *00x45086 17.30 :* * XXX* * 220:00 19: * *8 * * * * * * XXX FIG.4A FIG.45 U . S . Patent Mar. 20 , 2018 Sheet 5 of 5 US 9 ,920 ,379 B2 FIG . 5A BLAH A24 - 3p 419 - 30 asa - -08 HANAIRNA FIG . 58 5W www4444444444444444 80074418 wwwnnnnnnnnnnn 6FR * * * * 50014 : dajad Soowon FRI t a tatatatatatatatatatatatatatatatatate 1408 32 28 w mw 3257 bo Osovodu in here Een the R ? NM FIG . 5C S com en 2018 60 243 moment US 9 , 920 , 379 B2 NUCLEIC ACIDS RELATED TO invention satisfies this need and provides a significant num MIR - 29B - 1 -5P AND USES THEREOF ber of miRNAs and uses therefore . FIELD OF THE INVENTION SUMMARY OF THE INVENTION 5 The invention relates in general to microRNA molecules The present invention is related to an isolated nucleic acid as well as various nucleic acid molecules relating thereto or comprising a sequence of a pri- miRNA , pre -miRNA , derived therefrom . miRNA , miRNA * , anti -miRNA , or a miRNA binding site , or a variant thereof. The nucleic acid may comprise the REFERENCES TO THE SEQUENCE LISTING 10 sequence of a hairpin referred to in Table 1 ; the sequence of AND TABLES a miRNA referred to in Table 1 ; the sequence of a target gene binding site referred to in Table 4 ; or a sequence comprising Applicant hereby makes reference to the sequence listing at least 12 contiguous nucleotides at least 60 % identical and tables that were submitted electronically via EFS -Web . thereto . The isolated nucleic acid may be from 5 - 250 nucleo The sequence listing consists of a filed named “ Sequence - 15 tides in length . Listing .txt , ” ( 20 KB ) , created on May 3 , 2017 . The tables The present invention is also related to a probe compris consist of the following files : “ Table1.
Load more

Recommended publications
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
    International Journal of Molecular Sciences Review The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia Marta Weronika Lato 1 , Anna Przysucha 1, Sylwia Grosman 1, Joanna Zawitkowska 2 and Monika Lejman 3,* 1 Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] (M.W.L.); [email protected] (A.P.); [email protected] (S.G.) 2 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 3 Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland * Correspondence: [email protected] Abstract: Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that ac- counts for 10–15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event-free survival rate (EFS) is 85%. The evaluation of structural and numerical chromosomal changes is important for a comprehensive biological characterization of T-ALL, but there are currently no ge- netic prognostic markers. Despite chemotherapy regimens, steroids, and allogeneic transplantation, relapse is the main problem in children with T-ALL. Due to the development of high-throughput molecular methods, the ability to define subgroups of T-ALL has significantly improved in the last few years. The profiling of the gene expression of T-ALL has led to the identification of T-ALL subgroups, and it is important in determining prognostic factors and choosing an appropriate treatment. Novel therapies targeting molecular aberrations offer promise in achieving better first remission with the Citation: Lato, M.W.; Przysucha, A.; hope of preventing relapse.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer
    GENES, CHROMOSOMES & CANCER 47:1049–1066 (2008) Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer L. W. M. Loo,1 C. Ton,1,2 Y.-W. Wang,2 D. I. Grove,2 H. Bouzek,1 N. Vartanian,1 M.-G. Lin,1 X. Yuan,1 T. L. Lawton,3 J. R. Daling,2 K. E. Malone,2 C. I. Li,2 L. Hsu,2 and P.L. Porter1,2,3* 1Division of Human Biology,Fred Hutchinson Cancer Research Center,Seattle,WA 2Division of Public Health Sciences,Fred Hutchinson Cancer Research Center,Seattle,WA 3Departmentof Pathology,Universityof Washington,Seattle,WA The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affy- metrix GeneChip® Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss 5 0.186 and 0.156). By comparing the average frequency of LOH by chro- mosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Supplementary Tables
    Supp Table 1. Patient characteristics of samples used for colony assays, xenografts and intracellular colony assays Sr.No Age Sex Diagnosis Blast% Cytogenetics Mutations (IPSS) (AF%) Patient samples used for colony assays 1. 68 F Low risk 1% N/A None MDS 2. 78 M RAEB-1 7% N/A DNMT3A 3. 66 F High risk 12.2% 5q-,7q-,+11, DNMT3A MDS 20q- (28%) TP53 (58%) 4. 61 M High risk 6.2% Monosomy 7 ASXL1 (36%) MDS EZH2 (77%) RUNX1(18%) 5. 63 M Low risk Normal ETV6 (34%), MDS KRAS(15%), RUNX1 (40%), SRSF2 (43%), ZRSR2 (86%) 6. 62 F RAEB-2 Del 5q TP53 (7%) 7. 76 F t-MDS <1% Normal TET2(10%) 8. 80 M Low risk 5% Normal SF3B1(21%) MDS TET2(8%) ZRZR2(62%) 9. 74 F MPN 5% JAK2V617F+ 10. 76 M Low risk <1% Deletion Y None MDS 11. 84 M Low risk N/A N/A N/A MDS 12. 86 M Int-2 MDS 4-8% Normal U2AF1 (43%) blasts CBL (15%) 13. 64 M low risk 1-3% 20q deletion ASXL1 (17%) MDS SETBP1(17%) U2AF1(15%) 14. 81 F Low risk <1% Normal None MDS Patient samples used for PDX 15. 87 F Int-2 risk 1.2% Complex SETBP1 (38%) MDS cytogenetics, del 7, dup 11, del 13q 16. 59 F High-risk 7-10% Complex NRAS (12%), MDS cytogenetics RUNX1 (20%), (-5q31, -7q31, SRSF2 (22%), trisomy 8, del STAG2 (17%) 11q23 17. 79 F Int-2 risk 5-8% None MDS 18. 67 M MPN 6.6% Normal CALR (51%) IDH1(47%) PDGFRB (47%) Patient samples used for intracellular ASO uptake 19.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • 140503 IPF Signatures Supplement Withfigs Thorax
    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.
    [Show full text]
  • Pan-Cancer Analysis of Homozygous Deletions in Primary Tumours Uncovers Rare Tumour Suppressors
    Corrected: Author correction; Corrected: Author correction ARTICLE DOI: 10.1038/s41467-017-01355-0 OPEN Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors Jiqiu Cheng1,2, Jonas Demeulemeester 3,4, David C. Wedge5,6, Hans Kristian M. Vollan2,3, Jason J. Pitt7,8, Hege G. Russnes2,9, Bina P. Pandey1, Gro Nilsen10, Silje Nord2, Graham R. Bignell5, Kevin P. White7,11,12,13, Anne-Lise Børresen-Dale2, Peter J. Campbell5, Vessela N. Kristensen2, Michael R. Stratton5, Ole Christian Lingjærde 10, Yves Moreau1 & Peter Van Loo 3,4 1234567890 Homozygous deletions are rare in cancers and often target tumour suppressor genes. Here, we build a compendium of 2218 primary tumours across 12 human cancer types and sys- tematically screen for homozygous deletions, aiming to identify rare tumour suppressors. Our analysis defines 96 genomic regions recurrently targeted by homozygous deletions. These recurrent homozygous deletions occur either over tumour suppressors or over fragile sites, regions of increased genomic instability. We construct a statistical model that separates fragile sites from regions showing signatures of positive selection for homozygous deletions and identify candidate tumour suppressors within those regions. We find 16 established tumour suppressors and propose 27 candidate tumour suppressors. Several of these genes (including MGMT, RAD17, and USP44) show prior evidence of a tumour suppressive function. Other candidate tumour suppressors, such as MAFTRR, KIAA1551, and IGF2BP2, are novel. Our study demonstrates how rare tumour suppressors can be identified through copy number meta-analysis. 1 Department of Electrical Engineering (ESAT) and iMinds Future Health Department, University of Leuven, Kasteelpark Arenberg 10, B-3001 Leuven, Belgium.
    [Show full text]
  • Pirfenidone Is Renoprotective in Diabetic Kidney Disease
    BASIC RESEARCH www.jasn.org Pirfenidone Is Renoprotective in Diabetic Kidney Disease ʈ Satish P. RamachandraRao,*†‡ Yanqing Zhu,‡ Timothy Ravasi,§ Tracy A. McGowan,‡ Irene Toh,‡ Stephen R. Dunn,‡¶ Shinichi Okada,*† Michael A. Shaw,** and Kumar Sharma*†‡ *Center for Renal Translational Medicine, Division of Nephrology-Hypertension, Department of Medicine, and ʈ §Department of Bioengineering, Jacobs School of Engineering, University of California, San Diego, Scripps NeuroAIDS Preclinical Studies Centre, and †Veterans Administration San Diego Healthcare System, La Jolla, California, ‡Center for Novel Therapies in Kidney Disease, Department of Medicine, ¶Cancer Genomics Facility, Kimmel Cancer Center, and **Proteomics and Mass Spectrometry Core Facility, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania ABSTRACT Although several interventions slow the progression of diabetic nephropathy, current therapies do not halt progression completely. Recent preclinical studies suggested that pirfenidone (PFD) prevents fibrosis in various diseases, but the mechanisms underlying its antifibrotic action are incompletely understood. Here, we evaluated the role of PFD in regulation of the extracellular matrix. In mouse mesangial cells, PFD decreased TGF-␤ promoter activity, reduced TGF-␤ protein secretion, and inhibited TGF-␤–induced Smad2-phosphor- ylation, 3TP-lux promoter activity, and generation of reactive oxygen species. To explore the therapeutic potential of PFD, we administered PFD to 17-wk-old db/db mice for 4 wk. PFD treatment significantly reduced mesangial matrix expansion and expression of renal matrix genes but did not affect albuminuria. Using liquid chromatography with subsequent electrospray ionization tandem mass spectrometry, we iden- tified 21 proteins unique to PFD-treated diabetic kidneys. Analysis of gene ontology and protein–protein interactions of these proteins suggested that PFD may regulate RNA processing.
    [Show full text]
  • Evolutionary Fate of Retroposed Gene Copies in the Human Genome
    Evolutionary fate of retroposed gene copies in the human genome Nicolas Vinckenbosch*, Isabelle Dupanloup*†, and Henrik Kaessmann*‡ *Center for Integrative Genomics, University of Lausanne, Ge´nopode, 1015 Lausanne, Switzerland; and †Computational and Molecular Population Genetics Laboratory, Zoological Institute, University of Bern, 3012 Bern, Switzerland Communicated by Wen-Hsiung Li, University of Chicago, Chicago, IL, December 30, 2005 (received for review December 14, 2005) Given that retroposed copies of genes are presumed to lack the and rodent genomes (7–12). In addition, three recent studies regulatory elements required for their expression, retroposition using EST data (13, 14) and tiling-microarray data from chro- has long been considered a mechanism without functional rele- mosome 22 (15) indicated that retrocopy transcription may be vance. However, through an in silico assay for transcriptional widespread, although these surveys were limited, and potential activity, we identify here >1,000 transcribed retrocopies in the functional implications were not addressed. human genome, of which at least Ϸ120 have evolved into bona To further explore the functional significance of retroposition fide genes. Among these, Ϸ50 retrogenes have evolved functions in the human genome, we systematically screened for signatures in testes, more than half of which were recruited as functional of selection related to retrocopy transcription. Our results autosomal counterparts of X-linked genes during spermatogene- suggest that retrocopy transcription is not rare and that the sis. Generally, retrogenes emerge ‘‘out of the testis,’’ because they pattern of transcription of human retrocopies has been pro- are often initially transcribed in testis and later evolve stronger and foundly shaped by natural selection, acting both for and against sometimes more diverse spatial expression patterns.
    [Show full text]